Regeneron Pharmaceuticals Inc. buy SVB Leerink LLC
Start price
28.03.23
/
50%
€753.50
Target price
28.03.24
-
Performance (%)
19.76%
End price
29.03.24
€902.40
Summary
This prediction ended on 29.03.24 with a price of €902.40. The prediction had a final performance of 19.76%. SVB_Leerink_LLC has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 5.664% | 5.664% | 24.160% | -8.124% |
| iShares Core DAX® | 1.770% | 3.450% | 5.562% | 60.302% |
| iShares Nasdaq 100 | -3.500% | 1.607% | 32.311% | 88.100% |
| iShares Nikkei 225® | -4.942% | 4.221% | 57.828% | 75.066% |
| iShares S&P 500 | 0.300% | 2.580% | 24.810% | 69.261% |
Comments by SVB_Leerink_LLC for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von SVB_Leerink_LLC gewählte maximale Laufzeit wurde überschritten